NIH Weekly Funding Opportunities and Policy Notices
Funding Opportunity PAR-23-193 from the NIH Guide for Grants and Contracts. The NICHD has a state-of-the-art Chemical Synthesis and Optimization Facility for advancing both non-hormonal contraceptive and reproductive health related product development. This facility has the capabilities and capacity for preclinical services including Investigational Device Exemption (IDE) or Investigational New Drug (IND)-enabling studies (e.g., protein generation, X-ray crystallography, high throughput screening, structure activity relationships, hit-to-lead generation, drug metabolism). The long-term objective is to enable a preclinical candidate for IND/IDE study(ies) that offers a safe therapeutic option in the field of contraception, and/or reproductive health related indications (pending contractor availability and available funding).
Notice NOT-AG-23-028 from the NIH Guide for Grants and Contracts
Notice NOT-MH-23-250 from the NIH Guide for Grants and Contracts
Notice NOT-OD-23-133 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-NS-24-003 from the NIH Guide for Grants and Contracts. This Notice of Funding Opportunity (NOFO) invites applications for a multisite study to comprehensively characterize ADRD relevant pathology related to cognitive impairment and dementia outcomes in persons with a history of traumatic brain injury (TBI). Investigations should elucidate the contribution of key individual (sex, age at time of injury, time since injury, social determinants of health, etc.) and injury characteristics (injury severity and frequency) to describe associations between neuropathological burden and antemortem clinicopathologic symptoms and outline the prevalence of TBI-related ADRD diagnoses, and CTE pathology in the participating brain banks. This NOFO intends to support applications that include retrospective samples, plans to acquire new brain tissue specimens, and methods to assess the antemortem symptomatology and clinical presentation. To further advance research in the area, broad sharing of clinical and neuropathological data will be a critical feature of successful applications, including the development of a digital resource for distribution and sharing of assessed neuropathological tissue.
Notice NOT-NS-23-085 from the NIH Guide for Grants and Contracts
Notice NOT-AG-23-027 from the NIH Guide for Grants and Contracts
Notice NOT-OD-23-124 from the NIH Guide for Grants and Contracts
Notice NOT-DE-23-011 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-HD-24-005 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity announcement (FOA) is to establish new Specialized Centers for Research on Health Disparities in Uterine Leiomyoma (SCHDULs). These centers will provide a platform to support novel, synergistic research programs involving multiple, high-quality projects spanning basic, clinical, translational, social sciences research to address health disparities (especially racial/ethnic disparities) in uterine fibroids.The established centers will aim to improve womens reproductive health and address modifiable aspects of the racial and associated health disparities in uterine fibroids through greater integrated understanding of biologic, behavioral, and environmental differences in risk, disease progression, and treatment.
Notice NOT-AA-23-013 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-AG-24-038 from the NIH Guide for Grants and Contracts. The purpose of this Notice of Funding Opportunity (NOFO) is to stimulate the use of existing biospecimens and datasets (i.e., secondary analysis) which will increase our understanding of the clinical significance of clonal hematopoiesis (CH) mutations, their causality, directionality, relationships with different human aging phenotypes, and the underlying biological mechanisms.
Funding Opportunity RFA-AG-24-036 from the NIH Guide for Grants and Contracts. The purpose of this initiative is to develop measures of financial hardship associated with AD/ADRD that are responsive to the dyadic and family-level financial management arrangements that are common as AD/ADRD progresses. In order to accurately measure financial hardship among people and families living with AD/ADRD, validated screeners are needed to capture unique hardships associated with AD/ADRD that are not measured in screeners developed for people with cancer or in screeners developed for healthy households. This Notice of Funding Opportunity (NOFO) invites research to support the development of measures of financial hardship for persons living with AD/ADRD and their partners, families, or caregivers to facilitate research on financial health-a key social determinant of health- and health related quality of life among older adults with AD/ADRD.
Funding Opportunity PAR-23-183 from the NIH Guide for Grants and Contracts. This Notice of Funding Opportunity (NOFO) solicits grant applications for the preparation of book-length manuscripts and other works of academic and/or public health importance to U.S. health professionals, public health officials, biomedical researchers and historians of the health sciences.
Notice NOT-HL-23-086 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-DA-24-029 from the NIH Guide for Grants and Contracts. The purpose of this FOA is to use multidisciplinary approaches to advance basic and clinical research and address key knowledge gaps on psychedelics. Given the therapeutic promise that psychedelics hold as neurotherapeutics, the goal is to systematically evaluate, and understand their mechanism of action and drug-target engagement, along with other translational aspects including their safety, pharmacokinetics/pharmacodynamics, and efficacy, in the context of substance use disorders (SUD).
Funding Opportunity RFA-DA-24-028 from the NIH Guide for Grants and Contracts. The overarching goal of this NIDA Notice of Funding Opportunity (NOFO) is to elucidate and validate the molecular, cellular, circuitry and structural mechanisms and pathways that underly the pharmacology of psychedelic compounds for treating substance use disorders (SUDs) and related psychiatric and neurological co-morbidities. This NOFO will also support the design and synthesis of chemical probes to provide mechanistic insights on biological targets modulated by psychedelics, and on common targets/pathways in the context of SUD. Research supported via this NIDA NOFO should facilitate transformative advances within the field that would primarily impact the activities of addictive drugs and/or addiction-relevant phenotypes.
Funding Opportunity RFA-DA-24-024 from the NIH Guide for Grants and Contracts. The purpose of this FOA is to use multidisciplinary approaches to advance basic and clinical research and address key knowledge gaps on psychedelics. Given the therapeutic promise that psychedelics hold as neurotherapeutics, the goal is to systematically evaluate, and understand their mechanism of action and drug-target engagement, along with other translational aspects including their safety, pharmacokinetics/pharmacodynamics, and efficacy, in the context of substance use disorders (SUD).
Funding Opportunity PAR-23-151 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity announcement (FOA) is to invite applications to support a national program of mentored research career development for junior emergency medicine faculty at institutions nationwide that support emergency medicine physicians to conduct research. The goal of the program is to expand the cadre of emergency medicine investigators trained to conduct research into neurological disorders, which makes use of their expertise associated with their clinical experience as emergency medicine clinicians.
Funding Opportunity RFA-AG-24-023 from the NIH Guide for Grants and Contracts. The central goal of this funding initiative is to evaluate the molecular, pathologic and functional consequences of major toxicants known to be associated with elevated AD/ADRD risk, in mouse models of Late Onset AD (LOAD). Projects funded through this program will examine the consequences of early and mid-life exposure on late-life brain health by conducting cross-sectional/longitudinal multi-modal phenotyping (molecular, biochemical, pathologic and behavioral) of mouse models of LOAD, and the impact of genetic diversity and sex-differences on exposure-related AD outcomes.